Laurence Leysen1,2, David Beckwée3,4, Jo Nijs5,3,6, Roselien Pas5,3, Thomas Bilterys3, Sofie Vermeir3, Nele Adriaenssens3,7. 1. Pain in Motion International Research Group, . laurence.leysen@vub.be. 2. Department of Physiotherapy, Human Physiology and Anatomy, Faculty of Physical Education and Physiotherapy, Vrije Universiteit Brussel, Building F-Kine, Laarbeeklaan 103, BE-1090, Brussels, Belgium. laurence.leysen@vub.be. 3. Department of Physiotherapy, Human Physiology and Anatomy, Faculty of Physical Education and Physiotherapy, Vrije Universiteit Brussel, Building F-Kine, Laarbeeklaan 103, BE-1090, Brussels, Belgium. 4. Department of Rehabilitation Sciences and Physiotherapy, Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium. 5. Pain in Motion International Research Group. 6. Department of Oncology, University Hospital Brussels, Brussels, Belgium. 7. Department of Physical Medicine and Physiotherapy, University Hospital Brussels, Brussels, Belgium.
Abstract
BACKGROUND: Breast cancer remains the number 1 lethal malignancy in women. With rising incidence and decreased mortality, the number of breast cancer survivors has increased. Consequently, sequelae, such as pain, are becoming more important. PURPOSE: The purpose of this study was to identify risk factors for the development of pain in breast cancer survivors. METHODS: PubMed and Web of Science were systematically screened for studies encompassing risk factors for the development of pain in breast cancer survivors. Meta-analyses were carried out for risk factors described in more than one article. Moderator analysis was performed in case of high heterogeneity (I 2 > 50%) across studies. RESULTS: Seventeen studies were found eligible. Meta-analyses were performed for 17 factors. Significant differences for the odds of developing chronic pain were found for BMI (overall OR: 1.34, 95%CI 1.08-1.67, p = 0.008), education (overall OR: 1.23, 95%CI 1.07-1.42, p = 0.005), lymphedema (overall OR: 2.58, 95%CI 1.93-3.46, p < 0.00001), smoking status (overall OR: 0.75, 95%CI 0.62-0.92, p = 0.005), axillary lymph node dissection (overall OR: 1.25, 95%CI 1.04-1.52, p = 0.02), chemotherapy (overall OR: 1.44, 95%CI 1.24-1.68, p < 0.00001), and radiotherapy (overall OR: 1.32, 95%CI 1.17-1.48, p < 0.00001). After performing moderator analyses for age, comorbidities, hormone therapy, and breast surgery, hormone therapy became a significant risk factor as well (overall OR: 1.33, 95%CI 1.15-1.54, p = 0.0001). CONCLUSION: BMI > 30, education < 12-13 years, lymphedema, not smoking, axillary lymph node dissection, chemotherapy, hormone therapy, and radiotherapy were significantly associated with higher odds for the development of chronic pain, with lymphedema being the biggest risk factor. Lack of uniformity across the studies in defining pain, follow-up, measurement tools, and cut-off values for the diagnosis of pain was noted, resulting in greater inter-study variability.
BACKGROUND:Breast cancer remains the number 1 lethal malignancy in women. With rising incidence and decreased mortality, the number of breast cancer survivors has increased. Consequently, sequelae, such as pain, are becoming more important. PURPOSE: The purpose of this study was to identify risk factors for the development of pain in breast cancer survivors. METHODS: PubMed and Web of Science were systematically screened for studies encompassing risk factors for the development of pain in breast cancer survivors. Meta-analyses were carried out for risk factors described in more than one article. Moderator analysis was performed in case of high heterogeneity (I 2 > 50%) across studies. RESULTS: Seventeen studies were found eligible. Meta-analyses were performed for 17 factors. Significant differences for the odds of developing chronic pain were found for BMI (overall OR: 1.34, 95%CI 1.08-1.67, p = 0.008), education (overall OR: 1.23, 95%CI 1.07-1.42, p = 0.005), lymphedema (overall OR: 2.58, 95%CI 1.93-3.46, p < 0.00001), smoking status (overall OR: 0.75, 95%CI 0.62-0.92, p = 0.005), axillary lymph node dissection (overall OR: 1.25, 95%CI 1.04-1.52, p = 0.02), chemotherapy (overall OR: 1.44, 95%CI 1.24-1.68, p < 0.00001), and radiotherapy (overall OR: 1.32, 95%CI 1.17-1.48, p < 0.00001). After performing moderator analyses for age, comorbidities, hormone therapy, and breast surgery, hormone therapy became a significant risk factor as well (overall OR: 1.33, 95%CI 1.15-1.54, p = 0.0001). CONCLUSION: BMI > 30, education < 12-13 years, lymphedema, not smoking, axillary lymph node dissection, chemotherapy, hormone therapy, and radiotherapy were significantly associated with higher odds for the development of chronic pain, with lymphedema being the biggest risk factor. Lack of uniformity across the studies in defining pain, follow-up, measurement tools, and cut-off values for the diagnosis of pain was noted, resulting in greater inter-study variability.
Entities:
Keywords:
Breast cancer survivor; Chronic pain; Pain; Risk factors
Authors: Raimund Jakesz; Walter Jonat; Michael Gnant; Martina Mittlboeck; Richard Greil; Christoph Tausch; Joern Hilfrich; Werner Kwasny; Christian Menzel; Hellmut Samonigg; Michael Seifert; Guenther Gademann; Manfred Kaufmann; Johann Wolfgang Journal: Lancet Date: 2005 Aug 6-12 Impact factor: 79.321
Authors: Enja J Bantema-Joppe; Cornelis Schilstra; Geertruida H de Bock; Wil V Dolsma; Dianne M Busz; Johannes A Langendijk; John H Maduro Journal: Int J Radiat Oncol Biol Phys Date: 2012-04-10 Impact factor: 7.038
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: G J van Londen; E B Beckjord; M A Dew; K L Cooper; N E Davidson; D H Bovbjerg; H S Donovan; R C Thurston; J Q Morse; S Nutt; R Rechis Journal: Support Care Cancer Date: 2013-11-24 Impact factor: 3.603
Authors: Tao Wang; Yu-Yan Huang; Xian-Liang Liu; Alex Molassiotis; Li-Qun Yao; Si-Lin Zheng; Jing-Yu Benjamin Tan; Hou-Qiang Huang Journal: Support Care Cancer Date: 2022-09-06 Impact factor: 3.359
Authors: Julius K Weng; Xiudong Lei; Pamela Schlembach; Elizabeth S Bloom; Simona F Shaitelman; Isidora Y Arzu; Gregory Chronowski; Tomas Dvorak; Emily Grade; Karen Hoffman; George Perkins; Valerie K Reed; Shalin J Shah; Michael C Stauder; Eric A Strom; Welela Tereffe; Wendy A Woodward; Gabriel N Hortobagyi; Kelly K Hunt; Thomas A Buchholz; Benjamin D Smith Journal: Int J Radiat Oncol Biol Phys Date: 2021-05-13 Impact factor: 8.013
Authors: Astrid Lahousse; Eva Roose; Laurence Leysen; Sevilay Tümkaya Yilmaz; Kenza Mostaqim; Felipe Reis; Emma Rheel; David Beckwée; Jo Nijs Journal: J Clin Med Date: 2021-12-30 Impact factor: 4.241
Authors: Anna Jansana; Isabel Del Cura; Alexandra Prados-Torres; Teresa Sanz Cuesta; Beatriz Poblador-Plou; A Gimeno Miguel; Manuela Lanzuela; Berta Ibañez; Ibai Tamayo; Conchi Moreno-Iribas; María Padilla-Ruiz; Maximino Redondo; Mercè Comas; Laia Domingo; Antonio Díaz-Holgado; Francisco Javier Salamanca; Xavier Castells; Maria Sala Journal: BMJ Open Date: 2020-09-09 Impact factor: 2.692
Authors: Mei Rosemary Fu; Deborah Axelrod; Amber Guth; Melissa L McTernan; Jeanna M Qiu; Zhuzhu Zhou; Eunjung Ko; Cherlie Magny-Normilus; Joan Scagliola; Yao Wang Journal: Biomedicines Date: 2021-07-14